| PRECLINICAL | evidence | Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records. | Zepbound | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Correction: Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Societa Italiana Obesita) Italian guidelines for the diagnosis and treatment of overweight and obesity. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Metabolic inflammation at the adipose-brain axis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced? | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Correction: Weight loss efficiency and safety of tirzepatide: A Systematic review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | [Pharmacological treatment of obstructive sleep apnea syndrome]. | Tirzepatide | Sleep quality | 2026-01-01 |
| PRECLINICAL | evidence | Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. | Tirzepatide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence. | Tirzepatide | Lipid & cardiovascular markers | 2026-01-01 |
| PRECLINICAL | evidence | Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | Incretin therapy and obesity: current and future pharmacologic possibilities. | Zepbound | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | The effect of combining surgical or endoscopic bariatric interventions with anti-obesity medication or probiotics on weight loss: a narrative review. | Tirzepatide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders. | Tirzepatide | — | 2026-01-01 |
| PRECLINICAL | evidence | The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics. | Tirzepatide | Weight & fat loss | 2026-01-01 |